Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Kayne Anderson Energy Infrastructure Fund, Inc. announced a monthly distribution of $0.085 per share payable on June 30, 2026. The fund focuses on investing in securities of Energy Infrastructure Companies and aims to provide high after-tax total return with an emphasis on cash distributions. The distribution amount may vary and is subject to board…
PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a 76% controlling stake in a U.S.-based precision machining company specializing in high-tolerance CNC machining for aerospace, space, defense, semiconductor, and other industrial sectors. The target company is certified and compliant with industry standards, has recurring reve…
Immuneering Corporation announced updated data from its Phase 2a trial showing a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel chemotherapy, nearly double the survival seen in historical controls. The treatment demonstrated a favorable sa…
XCHG Limited, a Nasdaq-listed integrated EV charging and energy solutions company, appointed Albina Iljasov as Co-Chief Executive Officer effective June 1, 2026. Iljasov will oversee European operations and spearhead information security and cybersecurity efforts, complementing existing Co-CEO Yifei Hou. The move signals XCharge's commitment to glo…
Iovance Biotherapeutics announced FDA clearance of their investigational new drug (IND) application for IOV-5001, a next-generation interleukin-12 (IL-12) tethered tumor infiltrating lymphocyte (TIL) therapy. The Phase 1/2 trial aims to treat multiple advanced solid tumors including colorectal and breast cancers, with enrollment expected in the sec…
SL Green Realty Corp., Manhattan's largest office landlord, announced the sale of 10 East 53rd Street to Meadow Partners for $312.2 million. The sale, expected to close in Q3 2026, will generate approximately $100 million in net cash proceeds to reduce corporate debt. This transaction advances SL Green's $2.5 billion strategic disposition plan and …
Anterix Inc., a leading provider of private wireless broadband spectrum solutions for critical infrastructure, announced its fourth quarter fiscal 2026 earnings conference call will take place on June 11, 2026. The company will discuss its quarterly results following a press release after market close on June 10. Anterix continues to focus on deliv…
Cognition Therapeutics, a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced CEO Lisa Ricciardi will present at two upcoming investor conferences, sharing updates on the company's development plans for its lead drug candidate zervimesine (CT1812), targeting dementia with Lewy bodies (DLB) psychosis. The compan…
Cytokinetics announced the commercial launch of MYQORZO® (aficamten) in Germany, marking its first European availability for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows FDA approval and market introduction in the U.S. and China. The European Commission approved MYQORZO based on positive Phase 3 clinical trial results de…
OptimizeRx Corp., a healthcare technology company specializing in AI-driven marketing solutions for life sciences, announced that its management will participate in prominent investor conferences including the Stifel 2026 Boston Cross Sector Conference and the 46th Annual William Blair Growth Stock Conference. The participation aims to showcase the…
TG Therapeutics announced publication of post-hoc pooled analyses from the Phase 3 ULTIMATE I & II trials demonstrating that BRIUMVI (ublituximab-xiiy) provides significant clinical and MRI improvements versus teriflunomide in treatment-naïve adult patients with relapsing multiple sclerosis (RMS). The data supports early use of this high-efficacy t…
Intellia Therapeutics announced it will present additional data from its global Phase 3 HAELO trial of lonvo-z, a one-time CRISPR-based gene editing therapy for hereditary angioedema (HAE), at the EAACI 2026 Congress. This late-breaking oral presentation highlights the potential of lonvo-z to become the first permanent treatment to prevent HAE atta…
Athene, a leading retirement solutions company and subsidiary of Apollo Global Management, appointed Matthew Michelini as President of Athene Holding Ltd., effective July 1, 2026. Michelini brings extensive experience from Apollo, including leadership in Asia-Pacific, and will focus on advancing growth initiatives and reinventing guaranteed lifetim…
HCI Group successfully completed its 2026-2027 catastrophe reinsurance programs, securing $4.1 billion in excess of loss coverage, a 16% increase year-over-year, while reducing net reinsurance premiums by 10%. The company enhanced its risk transfer strategy with meaningful structural improvements and expanded participation of its Cayman Islands rei…
Nayax Ltd., a global payments and commerce enablement platform, launched a new AI-powered product discovery and personalization feature integrated into its platform. This solution helps retailers utilize real-time shopper data across multiple channels to provide personalized recommendations, thereby increasing customer engagement and sales. The pro…
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions, announced that Interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The company is advancing proprietary drugs HLP003 and HLP004 for major depressive…
BriaCell Therapeutics Corp. announced positive clinical data from Phase 2 and ongoing Phase 3 studies of its Bria-IMT immunotherapy for heavily pre-treated metastatic breast cancer patients at the 2026 ASCO Annual Meeting. Data demonstrated promising survival rates, good quality of life, and potential predictive biomarkers, supporting continued dev…
New Era Energy & Digital, Inc. announced participation in several major investor and industry conferences in June 2026, highlighting its leadership presence. The company also expects to be added to the Russell 3000 and Russell Microcap Indexes following the annual reconstitution, effective June 29, 2026. This inclusion signals increased visibility …
Edible Garden AG Incorporated has completed a major logistics overhaul in the Metro New York area, shifting from a Direct Store Delivery model to a direct-to-distribution-center and regional hub model. This change is expected to significantly reduce transportation costs and carbon emissions, improving operational efficiency and supporting the compa…
Piedmont Realty Trust announced that it has signed approximately 240,000 square feet of leases in the second quarter so far, with more than 60% representing new tenant leasing and 90% of new leases for previously vacant spaces. This brings the year-to-date leasing volume to approximately 670,000 square feet. The company highlights sustained high de…
IREN Limited has successfully closed a $3.65 billion investment-grade GPU financing facility, the largest publicly rated GPU financing to date, to support its AI Cloud contract with Microsoft. The facility includes a $2.10 billion U.S. private placement and a $1.55 billion delayed draw term loan, funding 96% of the $5.81 billion GPU capital expendi…
Science Applications International Corporation (SAIC) announced its Q1 FY2027 results with revenues of $1.91 billion, a 2% increase including acquisitions, and modest organic growth of 0.5%. The company reported adjusted EBITDA of $222 million, a 41% increase year-over-year, and adjusted diluted EPS of $3.23, up 68%. Cash flow from operations impro…
Invivyd, Inc., a U.S.-based biopharmaceutical company, announced the completion of enrollment in its Phase 3 DECLARATION clinical trial testing VYD2311, an investigational monoclonal antibody administered intramuscularly for the prevention of symptomatic COVID-19. The trial was upsized by approximately 500 subjects to enhance statistical power due …
Jade Biosciences announced positive interim Phase 1 trial results of JADE101, a novel anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN). Results demonstrated approximately 70% sustained IgA reduction at 12 weeks after a single dose, with potential for every 12-week subcutaneous maintenance dosing. JADE101 showed faster, deeper,…
Monopar Therapeutics presented Phase 2 clinical trial results of ALXN1840 at EASL 2026, demonstrating stabilization of liver disease and significant neurological improvements in treatment-experienced Wilson disease patients. The therapy was well tolerated and improved patients' quality of life, highlighting its potential as a novel treatment option…
